{"news_desk": "Business", "print_page": "2", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Gilead Sciences reports surging first quarter profits, with earnings per share more than doubling to $2.76 from year-earlier period; reports that sales of its hepatitis C drugs reached $4.55 billion, largely reflecting popularity of its new drug, Harvoni.", "type_of_material": "News", "word_count": "515", "lead_paragraph": "Sales of Harvoni and an earlier hepatitis C drug, Sovaldi, far exceeded Wall Street expectations and made the company one of the top earners in pharmaceuticals.", "pub_date": "2015-05-01T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Gilead Hepatitis Drugs Brought In $4.55 Billion in First Quarter", "print_headline": "Gilead Earnings Surge as Sales of Hepatitis Drugs Double, Exceeding Forecasts"}, "snippet": "Sales of Harvoni and an earlier hepatitis C drug, Sovaldi, far exceeded Wall Street expectations and made the company one of the top earners in pharmaceuticals.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/05/01/business/gilead-hepatitis-drugs-brought-in-4-55-billion-in-first-quarter.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Gilead Sciences Inc", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Hepatitis", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "Harvoni (Drug)", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Company Reports", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Prices (Fares, Fees and Rates)", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "7", "is_major": "N", "value": "Sovaldi (Drug)", "name": "subject"}], "blog": [], "_id": "554299de38f0d83d46e51e49", "source": "The New York Times"}